Drilldown: Medicines

None (1) · Bisoprolol (1) · Doxazosin (1) · Nebivolol (1) · Terazosin (1)

Bystolic (1) · Cardura, Cardura XL (1) · Hytrin (US brand discontinued); mostly generic (1) · Zebeta (1) · Zurzuvae (1)

Beta Blocker (2) · Cardioselective (β1) (1) · Cardioselective (β1) + vasodilator (1) · GABA-A positive allosteric modulator (oral) (1) · Neuroactive steroid (1) · [[:Category:Alpha-1_blockers|Alpha-1 adrenergic blocker (non-selective)]] (2) · [[:Category:Antihypertensives|Antihypertensive]] (2) · [[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (2)

None (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · Synthetic neuroactive steroid (an analog of allopregnanolone), bioavailable orally unlike brexanolone. Positive allosteric modulator at GABA-A receptors including extrasynaptic δ-containing subtypes. (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) · '"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)

Postpartum depression (PPD) in adults (FDA-approved 2023) (1) · '"`UNIQ--vote-0000059D-QINU`"' (1) · '"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1) · '"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) · '"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1)

1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) · 2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 5 mg daily (1) · 50 mg PO once daily with fatty food in the evening × 14 days (1) · IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1)

1, 2, 4, 8 mg IR tablets; 4, 8 mg XL tablets (1) · 1, 2, 5, 10 mg capsules and tablets (1) · 2.5, 5, 10, 20 mg tabs (1) · 20 mg, 25 mg, 30 mg capsules (1) · 5, 10 mg tabs (1)

16 mg/d (IR); 8 mg/d (XL) (1) · 20 mg/d (2) · 40 mg/d (1) · 50 mg/d × 14 d (1)

Oral (5)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

14-day course; effect persists after discontinuation in trials (1) · 24 h (2) · 24 hours (2)

9–12 h (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~12 hours'"`UNIQ--ref-0000111F-QINU`"' (1) · ~16-23 hours (1) · ~22 hours'"`UNIQ--ref-00000AB0-QINU`"' (1)

>90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' (1) · Adequate (food-dependent, must take with fatty meal) (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"' (1) · ~90% (low first-pass) (1)

Category C (2) · Limited data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; avoid in pregnancy. Lactation: present in milk; consider risks (1) · Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

Rx, Schedule IV (US) (1) · Rx-only in US (2) · [[USLegal:Prescription only|Rx-only]] in US (2)